Fat-burning target discovered, lying down to lose weight or become true
Fat-burning target discovered, lying down to lose weight or become true, Jinan University research team found that IL-27 (interleukin 27) can directly target and promote fat cell browning and thermogenesis, fat-burning target discovered, lying down to lose weight or become true.
Burning fat target was found, lying weight loss or become true1
November 29, the reporter from the University of Jinan (hereinafter referred to as Jinan University) was informed, Jinan University Institute of Biomedical Translational Research, Prof. Yin Zhinan team for the first time found that the interleukin (IL-27) can be directly targeting the role of the fat cells and promote fat cell thermogenesis, through the combustion of lipids, the consumption of calories, easy to lose weight. More critically, IL-27 can improve type 2 diabetes, providing a new target and potential drug for the treatment of obesity and its related metabolic diseases. Recently, Nature published this scientific research online.
"Insulin resistance is not only the cause of obesity, but also causes a series of metabolic diseases, including type 2 diabetes, fatty liver, ovarian polycystic syndrome, and so on. If the problem of insulin tolerance can be improved, obesity and many metabolic diseases may find better treatment pathways." Yin Zhinan said.
Yin Zhinan has long been engaged in basic and clinical research on immunity and health, and in 2014, he proposed to study obesity from the immune system to see if he could bring new avenues and hope for obesity treatment from an immune system perspective.
"We found through clinical observation that obese patients had low levels of IL-27 in their bodies, but after they completed bariatric surgery, their IL-27 levels returned to normal." Yin Zhinan said he and his team were particularly curious about whether the traditional idea of IL-27, which exclusively targets immune cells, could possibly be a new target for weight loss.
By constructing a variety of genetically engineered mice, the team used a high-fat diet-induced obesity model and combined it with samples from the obese population to find that serum levels of IL-27 do indeed decrease in the obese population. This study is the first to discover that IL-27, by directly acting on adipocytes, can lead to the browning of white adipocytes and activate "fat-burning"; by converting lipids in adipose tissue into calories to be burned off, thus achieving the purpose of reducing body weight and improving the metabolic diseases such as diabetes. This study breaks through the traditional perception that IL-27 specifically targets immune cells.
In animal experiments, injection of recombinant IL-27 significantly reduced body weight and improved insulin signaling sensitivity in obese mice, preliminarily validating the potential of IL-27 as a therapeutic drug. "The fundamental reason why type 2 diabetes is so difficult to overcome is the diminished response to insulin signaling. Insulin is like a key, and the overall signal that responds to it is a lock. If the lock is rusty, when the key is inserted, you can't get the lock open by twisting it halfway." Wang Qian, the first author of the paper and a postdoctoral fellow at Zhuhai People's Hospital affiliated with JIU, said, "We now find that IL-27's role is equivalent to lubricating the eye of the lock, so that the key can be inserted to open the lock immediately, thus improving the patient's overall disordered state and restoring the patient's blood glucose to a healthy level."
Because IL-27 is a normally expressed molecule in the body and not a synthetic exogenous compound, it is safe. "It can improve type 2 diabetes without dietary restriction or dieting, burn fat, lose weight, and mechanistically improve the sensitivity of insulin signaling response." Postdoctoral fellow Dehai Li, another first author of the paper and affiliated with Zhuhai People's Hospital of JIU, introduced.
"We look forward to industrializing this therapeutic target as soon as possible, promoting its clinical application, and developing RNA-related drugs to provide a new treatment for a series of metabolic diseases such as obesity, diabetes, fatty liver, and so on." Yin Zhinan also revealed another research direction, through the IL-27 level changes, to predict the physical health condition.
However, he also emphasized at the same time that there is still a long way to go from the lab to the clinic, which requires the ****ing efforts of policy, investment and other aspects.
Burning fat target was found, lying down to lose weight or become true2Yesterday, Jinan University, Professor Yin Zhinan team of major scientific research results transfer signing ceremony and the key innovations on the journal "Nature" press conference was held. The reporter learned at the meeting, Jinan University research team found for the first time, IL-27 (interleukin 27) can be directly targeted and promote adipocyte browning and thermogenesis, activate the "fat burning", through the burning of lipids, to reduce obesity, improve the metabolic diseases such as type 2 diabetes, for the treatment of obesity and metabolic diseases provide a new target. This is a new target for the treatment of obesity and metabolic diseases.
Research:
Converting fat into calories
On November 24, 2021, Professor Yin Zhinan's team at the Institute of Biomedical Translational Research (IBTR) of the Department of Medicine at Jinan University published an article titled "IL-27 signaling promotes adapted fat burning" in the online journal Nature. "IL-27 signaling promotes adipocyte thermogenesis and energy expenditure".
In this research work, the researchers constructed a variety of genetically engineered mice for high-fat diet-induced obesity modeling, and combined with samples from the obese population, found that: serum levels of IL-27 in the obese population were decreased; broke through the conventional `knowledge' that the interleukin IL-27 exclusively targets immune cells, and for the first time, found that IL-27 can directly act on adipocytes, causing It is the first time that IL-27 can act directly on adipocytes, leading to the browning of white adipocytes and the activation of UCP1-mediated "fat burning"; by converting lipids in the adipose tissue into calories to be burned off, it can achieve the purpose of lowering body weight and ameliorating metabolic diseases, such as diabetes.
Functions:
May stop diabetics from taking medication
"Weight gain is superficially a result of enlarged fat cells, but the underlying cause is insulin resistance. " Prof. Yin Zhinan explained that the team's discovery of IL27 acting on fat cells 'burning', on the one hand, can lose weight, but the main thing is to improve insulin resistance. Improved insulin tolerance has great significance for the treatment of obesity and many diseases, such as fatty liver, polycystic ovary syndrome.
"IL27 improves type 2 diabetes without dieting, 'burns fat' and reduces weight, and is mechanistically improving insulin signaling sensitivity." The paper***Same first author and two postdoctoral fellows from Zhuhai People's Hospital affiliated with Jinan University - Dehai Li and Qian Wang - explained that the main advantage of the research results is that IL-27 is a protein expressed in the body, not a synthetic exogenous compound.As a molecule that is normally expressed in the body, IL-27 has a good safety profile and has great potential for clinical application and market value.
In animal experiments, injection of recombinant IL-27 significantly reduced body weight and improved insulin signaling sensitivity in obese mice, initially validating the potential of IL-27 as a therapeutic drug. Prof. Yin Zhinan further introduced, "If applied as a drug, if it can improve insulin resistance, it is possible to do so that diabetic patients no longer take medication." He also said that it would take at least five years from the research to the emergence of the drug in an ideal situation.
Could this research be used to address weight loss in the general population? Prof. Yin Zhinan explained that it could be used to test the level of IL-27 to predict whether a person will become fat or not, i.e. to give an early warning of obesity. The team is currently developing a kit to detect IL-27.
The fat-burning target was found, lying down to lose weight or become a real 3Obesity and related metabolic diseases or a new way of treatment! November 25, Jinan University, Professor Yin Zhinan team of major scientific research results of the transfer of the signing ceremony and the focus of the innovative results on the journal "Nature" press conference was held. At the meeting, the reporter learned that the research team of Jinan University found for the first time that IL-27 (interleukin 27) can directly target and promote adipocyte browning and thermogenesis, activate "fat burning", and through the burning of lipids to reduce obesity, improve metabolic diseases such as type 2 diabetes mellitus, and provide new targets for the treatment of obesity and metabolic diseases. This is a new target for the treatment of obesity and metabolic diseases.
Research: converting fat into calories
On November 24, 2021, Professor Yin Zhinan's team at the Institute of Biomedical Translational Research at the Jinan University School of Medicine published an article titled "IL-27 signaling promotes adipocyte thermogenesis" (IL-27 signaling) online in the journal Nature. IL-27 signaling promotes adipocyte thermogenesis and energy expenditure" was published online in Nature.
This study breaks through the conventional perception that interleukin IL-27 exclusively regulates the immune system, and finds for the first time that IL-27 can directly target and promote adipocyte browning and thermogenesis, which reduces obesity and ameliorates type 2 diabetes by burning lipids.
What does adipocyte browning mean? According to reports, adipocytes are divided into white fat, brown fat and beige fat according to their morphology, metabolism, location and development. Among them, distributed in the body of subcutaneous tissue and viscera around the white fat, is the obesity "real culprit", its function is to the body of excess energy stored for the body in the need to use. Brown fat is mainly distributed in the human body between the shoulder blades, neck back, armpits, mediastinum and around the kidneys, contains a large number of mitochondria, with the function of burning fat and thermogenesis; beige fat is mainly distributed in the white adipose tissue in a number of grandmother cells and white cells, but also has the function of burning fat and thermogenesis.
In this work, the researchers constructed a variety of genetically engineered mice for high-fat diet-induced obesity model, and combined with samples from the obese population found that: interleukin 27 (IL-27) levels in the serum of the obese population declined; broke through the traditional concept of interleukin IL-27 exclusively targeting the immune cells of the perception of the first time to find that the IL-12 cytokine family of IL-27, a member of the IL-12 family of cytokines, was found to act directly on adipocytes, leading to the browning of white adipocytes and the activation of UCP1-mediated "fat burning"; by converting lipids in adipose tissue into calories that are burned off, the goal is to reduce body weight and ameliorate metabolic diseases such as diabetes.
Function: may allow diabetics to stop taking medication
"Weight gain, on the surface, is due to enlarged fat cells, but the root cause is insulin resistance." Prof. Yin Zhinan explained that the team's discovery of IL27 acts on fat cell burning, on the one hand to lose weight, but most of all to improve insulin resistance. Improved insulin tolerance is of great significance in the treatment of obesity and many diseases, such as fatty liver and polycystic ovary syndrome.
"IL27 improves type 2 diabetes, burns fat, and reduces weight without dietary restriction, that is, without dieting, and is mechanistically improving insulin signaling sensitivity." Li Dehai and Wang Qian, the paper***s co-first authors and 2 postdoctoral fellows at Zhuhai People's Hospital affiliated with Jinan University, explained that the main advantage of the research results is that IL-27 is a protein expressed in the homeodomain, not a synthetic exogenous compound. "That is, this protein is inherent in our body itself."
This study provides a new target for the treatment of obesity and metabolic diseases.IL-27, as a normally expressed molecule in vivo, has a favorable safety profile and has great potential for clinical application and market value. In animal experiments, injection of recombinant IL-27 significantly reduced body weight and improved insulin signaling sensitivity in obese mice, initially validating the potential of IL-27 as a therapeutic drug.
Prof. Zhinan Yin further explained, "The results of this study are currently safe from animal experiments. In the future, if it is applied as a drug, if it can improve insulin resistance, it is possible to do so that diabetic patients no longer take medication." And from the research to the drug, Prof. Yin Zhinan pointed out that ideally it would take at least five years.
Future: can give the average person an early warning of obesity
Can this research be used in the average person to lose weight? Prof. Yin Zhinan explains that IL-27 levels can be detected to predict whether a person will become fat or not, that is, to give an early warning of obesity. For example, people with low IL-27 levels should be careful to avoid a high-fat diet. The team is also currently developing a kit to detect IL-27.
"Which cell produces IL-27 during obesity, is IL-27 affected by other cells during fat cell interactions, and is it affected by emotions? These are the basic research the team will do next." Prof. Zhinan Yin said.
Professor Yin Zhinan introduced, this work took seven years, team members *** with the same efforts, and many experts and scholars at home and abroad to support and help to complete, his team looks forward to the industrialization of this therapeutic target as soon as possible, and hope that the results can benefit the majority of obese people.